Analysis on effectiveness of precise antiplatelet therapy guided by CYP2C19 gene polymorphism detection in patients with cerebral ischemic stroke

Xu Jin; Li Nenghong; Li Hui; Jiang Ying

doi:10.3969/j.issn.1674-7151.2025.03.001

Abstract：Objective To analyze the application effect of CYP2C19 gene polymorphism detection as an auxiliary clinical tool in precision treatment of ischemic stroke(CIS).Methods The 76 patients with CIS who received precise antiplatelet therapy at Langxi County People's Hospital from January 2024 to April 2025 were selected as study subjects and included in observation group.In addition,80 patients with CIS who received conventional antiplatelet therapy were included in control group.The clinical treatment efficacy was evaluated using modified Rankin Scale(mRS),Activity of Daily Living Scale(ADL)and incidence of adverse drug reactions.Results After 3 months of treatment,the mRS score in observation group was significantly lower than that in control group,and the ADL score was significantly higher than that in control group,with statistically significant differences(mRS score:1.26±0.51 vs.1.78±0.62;ADL score:68.36±8.12 vs.52.67±7.63;both P<0.05).The survival analysis results showed that the observation group had a significantly higher probability of non recurrence survival than the control group,and the difference was statistically significant(χ2=4.219,P=0.040).The incidence of adverse reactions in observation group was significantly higher than that in control group,and the difference was statistically significant(11.8%vs.1.3%,P<0.05).Conclusions Precise antiplatelet therapy could effectively improve the neurological function and self-care ability of CIS patients,but at the same time,it may increase the incidence of adverse drug reactions such as bleeding events and respiratory distress.Clinical practice needs to strengthen multidisciplinary consultation,develop personalized drug treatment plans,and reduce the occurrence of adverse drug events.